ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Infringement Lawsuit

Stock Information for ChromaDex Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ChromaDex Corporation

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured(TM) Transparency Program
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.